TL 118

Drug Profile

TL 118

Alternative Names: Hamsa 1; TL-111; TL-112

Latest Information Update: 07 Oct 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tiltan Pharma
  • Class Nonsteroidal anti-inflammatories; Sulfonamides
  • Mechanism of Action Alkylating agents; Angiogenesis inhibitors; Histamine H2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer
  • No development reported Prostate cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 06 Oct 2017 TL 118 is still at phase II development stage for Pancreatic cancer (Adjuvant therapy, Metastatic disease) in Israel and USA (PO,suspension) (Tiltan Pharma website, October 2017)
  • 06 Oct 2017 No recent reports on development identified - Phase-II for Prostate cancer (Hormone refractory, Metastatic disease) in Israel (PO,suspension)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top